Molecular Partners AG (MOLN.SW)
CHF 4.83
(4.43%)
CHF 4.83
(4.43%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -61.98 Million CHF | -152.59% |
| 2022 | 117.85 Million CHF | 284.77% |
| 2021 | -63.78 Million CHF | -1.63% |
| 2020 | -62.76 Million CHF | -72.96% |
| 2019 | -36.28 Million CHF | 2.02% |
| 2018 | -37.03 Million CHF | -45.64% |
| 2017 | -25.43 Million CHF | -36.63% |
| 2016 | -18.61 Million CHF | -12406.13% |
| 2015 | -148.82 Thousand CHF | 93.48% |
| 2014 | -2.28 Million CHF | -131.96% |
| 2013 | 7.14 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -11.32 Million CHF | 42.75% |
| 2024 Q3 | -16.4 Million CHF | -8.77% |
| 2024 Q2 | -15.08 Million CHF | -33.17% |
| 2023 Q2 | -15.98 Million CHF | -4.33% |
| 2023 Q1 | -15.32 Million CHF | 25.39% |
| 2023 Q4 | -19.78 Million CHF | -72.92% |
| 2023 Q3 | -11.43 Million CHF | 28.45% |
| 2023 FY | -61.98 Million CHF | -152.59% |
| 2022 Q3 | -12.09 Million CHF | -353.49% |
| 2022 Q1 | 153.12 Million CHF | 955.03% |
| 2022 FY | 117.85 Million CHF | 284.77% |
| 2022 Q4 | -20.53 Million CHF | -69.87% |
| 2022 Q2 | -2.66 Million CHF | -101.74% |
| 2021 Q1 | -16.55 Million CHF | 23.24% |
| 2021 Q2 | -17.01 Million CHF | -2.77% |
| 2021 FY | -63.78 Million CHF | -1.63% |
| 2021 Q4 | -17.9 Million CHF | -45.5% |
| 2021 Q3 | -12.3 Million CHF | 27.65% |
| 2020 Q2 | -11.4 Million CHF | 14.55% |
| 2020 Q3 | -16.44 Million CHF | -44.25% |
| 2020 FY | -62.76 Million CHF | -72.96% |
| 2020 Q1 | -13.34 Million CHF | -13.36% |
| 2020 Q4 | -21.56 Million CHF | -31.11% |
| 2019 Q2 | -6.37 Million CHF | 0.0% |
| 2019 FY | -36.28 Million CHF | 2.02% |
| 2019 Q4 | -11.77 Million CHF | 0.0% |
| 2019 Q3 | -11.77 Million CHF | -84.75% |
| 2019 Q1 | -6.37 Million CHF | 49.66% |
| 2018 Q4 | -12.65 Million CHF | 0.0% |
| 2018 FY | -37.03 Million CHF | -45.64% |
| 2018 Q1 | -5.86 Million CHF | -93.62% |
| 2018 Q2 | -5.86 Million CHF | 0.0% |
| 2018 Q3 | -12.65 Million CHF | -116.01% |
| 2017 Q3 | -3.02 Million CHF | 74.3% |
| 2017 FY | -25.43 Million CHF | -36.63% |
| 2017 Q4 | -3.02 Million CHF | 0.0% |
| 2017 Q2 | -11.77 Million CHF | -54.96% |
| 2017 Q1 | -7.6 Million CHF | -99.37% |
| 2016 Q3 | -5.1 Million CHF | 7.81% |
| 2016 Q4 | -3.81 Million CHF | 25.25% |
| 2016 FY | -18.61 Million CHF | -12406.13% |
| 2016 Q1 | -4.2 Million CHF | -410.88% |
| 2016 Q2 | -5.53 Million CHF | -31.71% |
| 2015 Q3 | 5.5 Million CHF | 218.19% |
| 2015 Q2 | -4.65 Million CHF | -93.9% |
| 2015 FY | -148.82 Thousand CHF | 93.48% |
| 2015 Q1 | -2.4 Million CHF | 50.85% |
| 2015 Q4 | 1.35 Million CHF | -75.44% |
| 2014 Q4 | -4.88 Million CHF | -543.89% |
| 2014 Q3 | 1.1 Million CHF | 44.95% |
| 2014 Q2 | 758.87 Thousand CHF | -0.0% |
| 2014 Q1 | 758.87 Thousand CHF | 232.93% |
| 2014 FY | -2.28 Million CHF | -131.96% |
| 2013 Q2 | 1.78 Million CHF | 0.0% |
| 2013 FY | 7.14 Million CHF | 0.0% |
| 2013 Q1 | 1.78 Million CHF | 0.0% |
| 2013 Q4 | -570.9 Thousand CHF | -131.98% |
| 2013 Q3 | 1.78 Million CHF | 0.0% |
| 2012 Q4 | 1.78 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.55 Million CHF | -487.179% |
| BB Biotech AG | -206.6 Million CHF | 69.999% |
| Basilea Pharmaceutica AG | 10.45 Million CHF | 693.092% |
| Evolva Holding SA | -105.22 Million CHF | 41.096% |
| Idorsia Ltd | -297.92 Million CHF | 79.194% |
| Kuros Biosciences AG | -13.72 Million CHF | -351.548% |
| Relief Therapeutics Holding AG | -98.18 Million CHF | 36.868% |
| Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | 213.147% |